Zacks Research Comments on Elevance Health Q2 Earnings

Elevance Health, Inc. (NYSE:ELV) – Stock analysts at Zacks Research lifted their Q2 2027 earnings estimates for Elevance Health in a report issued on Tuesday, November 3rd. Zacks Research analyst Team now anticipates that the company will earn $7.88 per share for the quarter, up from their prior forecast of $7.43. The consensus estimate for Elevance Health’s current full-year earnings is $29.18 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2027 earnings at $4.35 EPS, FY2027 earnings at $29.97 EPS, Q2 2028 earnings at $8.50 EPS and FY2028 earnings at $33.39 EPS.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the prior year, the company posted $6.03 earnings per share.

A number of other brokerages have also issued reports on ELV. UBS Group increased their price target on Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. The Goldman Sachs Group restated a “neutral” rating and issued a $451.00 price objective on shares of Elevance Health in a research report on Friday, October 23rd. Royal Bank Of Canada upped their price objective on Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 22nd. Guggenheim increased their target price on Elevance Health from $460.00 to $485.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Finally, Leerink Partners lifted their target price on Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $456.48.

Elevance Health Stock Down 0.1%

ELV opened at $413.11 on Wednesday. The stock has a market cap of $89.26 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 1.97 and a beta of 0.63. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. The firm’s fifty day moving average is $411.08 and its 200 day moving average is $372.73. Elevance Health has a fifty-two week low of $274.84 and a fifty-two week high of $450.69.

Institutional Investors Weigh In On Elevance Health

Several institutional investors have recently modified their holdings of the stock. Activest Wealth Management raised its holdings in Elevance Health by 146.2% during the 3rd quarter. Activest Wealth Management now owns 64 shares of the company’s stock valued at $25,000 after buying an additional 38 shares during the period. Kilter Group LLC purchased a new position in Elevance Health during the second quarter worth $28,000. WealthCollab LLC boosted its stake in Elevance Health by 42.2% during the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after buying an additional 27 shares during the period. Elevation Wealth Partners LLC boosted its stake in Elevance Health by 600.0% during the second quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after buying an additional 90 shares during the period. Finally, Tacita Capital Inc bought a new position in Elevance Health during the second quarter valued at $44,000. 89.24% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of the business’s stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.34% of the company’s stock.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is currently 29.34%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.